The Hemostatic Agents Market in the Asia Pacific is expected to grow at a relatively higher CAGR. Baxter (the leading organization in the global market), plans to expand its operation in emerging nations such as India and China to enhance its accessibility. This is expected to propel the growth rate of the Asia Pacific hemostatic agents market. Meanwhile, the Europe market is likely to expand at a low CAGR due to the presence of a smaller patient pool compared to the Asia Pacific and North America.
Browse Complete Report Details @
“Some of the Main Key Players Covered in the Report”
- Ethicon LLC.
- Pfizer Inc.
- Baxter International Inc.
- CryoLife Inc.
- Integra Life Sciences
“Combination Hemostats to Dominate the Global Market”
In terms of product type, the combination hemostats segment accounted for 14% of the global market in 2017. Combination hemostats are proven to be very effective and offer faster healing. Combination hemostats are capable of offering efficient hemostasis in shorter time owing to the rapid action of thrombin and gelatin. Rising adoption of combination hemostats is anticipated to drive the global hemostatic agents Industry during the forecast period 2018-2025.
Order Full Report @ https://www.fortunebusinessinsights.com/checkout-page/100084
The factors expected to drive the global market are increasing the incidence of hemorrhage during surgery and a rising emphasis on blood management. Moreover, innovations in a surgical procedure such as robot-assisted surgery and rising geriatric population are anticipated to fuel the demand in global hemostatic agents Industry.
By Product Type
- Active Hemostats
- Passive Hemostats
- Combination Hemostats
- Cardiovascular Surgery
- General Surgery
- Plastic Surgery
- Orthopedic Surgery
- Others (OBGYN, Urology, transplant, etc.)
By End User
- Ambulatory Surgical Centers
- Tactical Combat Casualty Care Centers
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
“Baxter Widening its Distribution Network Across Regions”
Baxter emerged dominant in the global hemostatic agents market in 2017. The growth witnessed is attributable to its diversification strategy implemented to improve the accessibility of its brands. The trend is unlikely to change and Baxter may continue to dominate the global market during the forecast period.
Strong brand presence, diversified product portfolio, and intense R&D conducted on hemostatic agents are a few factors contributing to Baster’s expansion
The report classifies the Global Hemostatic Agents Market in terms of various segments and offers a comprehensive overview. According to the report, the hemostatic agents market in North America was valued at US$ 1173 Mn in 2017.
Some of the other companies operating in the global hemostatic agents market are Stryker, CryoLife Inc., Integra Life Sciences, BD, Ethicon LLC., Pfizer Inc., Medtronic, and Biom’up.
“More Trending Topics from Fortune Business Insights”